At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 305 enrolled
Drug / intervention
Dexlansoprazole +1 moredrug
Likely dose
Dexlansoprazole 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy of TAK-390MR (30 mg QD) Compared to Placebo on Relief of Nocturnal Heartburn in Subjects With Symptomatic Gastroesophageal Reflux Disease (GERD)
In Brief
A Phase 3 clinical trial evaluating Dexlansoprazole and Placebo for Gastroesophageal Reflux. Completed, enrolled 305 participants across 43 sites.
Detailed Summary
The purpose of this study is to determine whether Dexlansoprazole once daily (QD) is effective in treating patients with night heartburn.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroesophageal Reflux
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2008
Enrollment StartMar 2008
Primary CompletionMar 2009
TodayJul 2026
First PostedFeb 29, 2008
Enrollment StartMar 1, 2008
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 18.3 years ago
Interventions
Dexlansoprazoledrug
30 mg capsule, orally, once daily for 4 weeks
Placebodrug
1 capsule, orally, once daily for 4 weeks